Mozobil Boosts Stem Cells Before Bone Marrow Transplants
(HealthDay)
Unusual Little Blurbs
HealthDay - FRIDAY, Dec. 19 (HealthDay News) -- The Genzyme Corp. Drug
Mozobil (Plerixafor) has been approved by the U.S. Food and Drug
Administration to boost a person's blood stem cell count before a bone
Marrow transplant, the agency said in a news release.
Source: Yahoo! News: Biotechnology News
New therapeutic target for graft-vs-host disease could make bone marrow transplant safer. Graft-versus-host disease (GVHD) is a major complication of bone marrow transplant, a potentially curative treatment for patients with blood-borne cancers such as leukemia and lymphoma. Inhibiting Sirt-1 in a mouse model helped control GVHD without making tumor relapse more likely, report researchers. The inhibitor has already been proven safe in humans but would need further testing in patients with blood-borne cancers. Source 6a.